Advances in research on the complement system and cognitive impairment
Jie Gao1, Zhe Li1, Xinyue Zhang1
1Department of Anesthesiology, the First Hospital of China Medical University, 155 Nanjing North Street, Heping District, Shenyang 110001, Liaoning Province, China.
Immunobiology
|January 14, 2026
Summary
Cognitive impairment is linked to the complement system and neuroinflammation. Understanding this connection may lead to new treatments targeting the complement system for cognitive dysfunction.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Cognitive impairment presents a significant global health challenge with rising prevalence and mortality.
- The complement system is increasingly recognized for its critical role in the pathological processes underlying cognitive dysfunction.
- Neuroinflammation is a key factor in the development of cognitive impairment, with the complement system implicated in its progression.
Purpose of the Study:
- To elucidate the intricate relationship between the complement system and neuroinflammation in the context of cognitive impairment.
- To explore the mechanisms through which the complement system contributes to cognitive dysfunction.
- To review the potential of complement inhibitors as therapeutic strategies for ameliorating and preventing cognitive impairment.
Main Methods:
- This review synthesizes current research on the complement system's role in neuroinflammation and cognitive decline.
- It examines the physiological functions of the complement system.
- The review analyzes the mechanisms linking complement activation to cognitive dysfunction and evaluates targeted treatment approaches.
Main Results:
- The complement system is intrinsically involved in neuroinflammatory processes that drive cognitive impairment.
- Specific pathways within the complement system contribute significantly to neuronal damage and cognitive deficits.
- Evidence suggests that modulating complement activity can impact the trajectory of cognitive dysfunction.
Conclusions:
- Targeting the complement system offers a promising therapeutic avenue for managing cognitive impairment.
- Further research into complement inhibitors is warranted for the development of effective treatments.
- A comprehensive understanding of complement-mediated neuroinflammation is crucial for advancing cognitive health strategies.
Related Concept Videos
01:27Complement System
9.8K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
9.8K
01:30Cognitive Development During Adulthood
780
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
780
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
560
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
560
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:17Cognitivism
2.9K
Cognitive psychology emerged as a significant field in the mid-20th century. It focused on understanding humans' internal mental processes. This approach emphasizes how people perceive, remember, think, and solve problems—elements critical to human cognition.
Previously dominated by behaviorism, which prioritized observable behaviors and largely ignored mental processes, psychology transformed in the 1950s. Cognitive psychologists argue that understanding how we think and process...
Previously dominated by behaviorism, which prioritized observable behaviors and largely ignored mental processes, psychology transformed in the 1950s. Cognitive psychologists argue that understanding how we think and process...
2.9K
01:22Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824